[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/17, TUE) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 셀렉티스, CAR-T→'인비보 염기편집' 변경.."인력 70%↓" 
[https://www.biospectator.com/news/view/30416](https://www.biospectator.com/news/view/30416)

 코히러스, 'CCR8' 식도암 제한 개발.."인력 30% 감축”
[https://www.biospectator.com/news/view/30400](https://www.biospectator.com/news/view/30400)

 루닛, RSNA서 'AI 진단 솔루션' 17건.."구두발표 11건"
[https://www.biospectator.com/news/view/30428](https://www.biospectator.com/news/view/30428)

 윈드워드, 나스닥 IPO 1.75억弗.."장기지속 TSLP 항체" 
[https://www.biospectator.com/news/view/30415](https://www.biospectator.com/news/view/30415)

 GC녹십자, 동방에프티엘과 'LNP 생산협력' MOU
[https://www.biospectator.com/news/view/30432](https://www.biospectator.com/news/view/30432)

 바이젠셀, ‘EBV T세포’ 식약처 신속처리대상 지정
[https://www.biospectator.com/news/view/30436](https://www.biospectator.com/news/view/30436)

 리제네론, 'NPR1 항체' 기립성 빈맥 2상 "심박급증 개선"
[https://www.biospectator.com/news/view/30414](https://www.biospectator.com/news/view/30414)

 롯데바이오로직스, 글로벌社와 'CMO' 수주계약 "체결" 
[https://www.biospectator.com/news/view/30434](https://www.biospectator.com/news/view/30434)

 헨리우스, 앱클론 'HER2 항체' 위암 HER2 low 2상 "추가"
[https://www.biospectator.com/news/view/30438](https://www.biospectator.com/news/view/30438)

 아리바이오, 'PDE5 저해제' AD 3상 "전체환자군 1차 미충족" 
[https://www.biospectator.com/news/view/30429](https://www.biospectator.com/news/view/30429)

 HLB펩, '前롯데바이오 대표' 이원직 사장 영입
[https://www.biospectator.com/news/view/30443](https://www.biospectator.com/news/view/30443)

 10년 데이터로 본 “中, 폭발적 성장과 3가지 요인은?” 
[https://www.biospectator.com/news/view/30141](https://www.biospectator.com/news/view/30141)  

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/17, TUE) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)